✦ LIBER ✦

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

✍ Scribed by Maira, S.-M.; Pecchi, S.; Huang, A.; Burger, M.; Knapp, M.; Sterker, D.; Schnell, C.; Guthy, D.; Nagel, T.; Wiesmann, M.

Book ID: 111950218
Publisher: American Association for Cancer Research
Year: 2011
Tongue: English
Weight: 727 KB
Volume: 11
Category: Article
ISSN: 1535-7163
DOI: 10.1158/1535-7163.mct-11-0474

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I, Dose-Escalation Study of BKM120

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

✍ Bendell, J. C.; Rodon, J.; Burris, H. A.; de Jonge, M.; Verweij, J.; Birle, D.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB

Phase I dose-escalation and -expansion s

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

✍ Rodon, Jordi; Braña, Irene; Siu, Lillian L; Jonge, Maja J; Homji, Natasha; Mills 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 925 KB

Identification and characterization of N

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

✍ Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; B 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 833 KB